
Success of phase 1 study is price trigger and strengthens Biosergen’s path to blockbuster drug
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an antifungal drug that is more
Del indlægget på sociale media eller på email.